# Nektar Therapeutics clinical trials: 39 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 39 trials with Nektar Therapeutics as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Nektar Therapeutics: 39 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/nektar-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 39
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 39, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 17, 2026 | NCT07711418 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis | Nektar Therapeutics | Phase 3 | Recruiting | Moderate-to-Severe Atopic Dermatitis | 510 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711418) |
| July 8, 2026 | NCT07690371 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis | Nektar Therapeutics | Phase 3 | Recruiting | Moderate-to-Severe Atopic Dermatitis | 510 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690371) |
| April 1, 2024 | NCT06340360 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients... | Nektar Therapeutics | Phase 2 | Completed | Alopecia Areata | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06340360) |
| November 18, 2023 | NCT06136741 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis | Nektar Therapeutics | Phase 2 | Active not recruiting | Moderate to Severe Atopic Dermatitis | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06136741) |
| December 23, 2022 | NCT05664217 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | Nektar Therapeutics | Phase 2/3 | Terminated | Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05664217) |
| October 4, 2022 | NCT05565729 | A Phase I Study of LY3471851 in Healthy Participants | Nektar Therapeutics | Phase 1 | Completed | Healthy | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05565729) |
| August 10, 2021 | NCT04998487 | A Single-Dose Study of LY3471851 in Healthy Participants | Nektar Therapeutics | Phase 1 | Completed | Healthy | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04998487) |
| July 21, 2021 | NCT04969861 | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | Nektar Therapeutics | Phase 2/3 | Terminated | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04969861) |
| July 8, 2021 | NCT04955262 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma... | Nektar Therapeutics | Phase 1 | Withdrawn | Metastatic Melanoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04955262) |
| December 21, 2020 | NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | Nektar Therapeutics | Phase 2 | Terminated | Colitis, Ulcerative | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04677179) |
| November 27, 2020 | NCT04646044 | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 | Nektar Therapeutics | Phase 1 | Completed | Covid-19, Coronavirus Disease 2019 | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04646044) |
| November 4, 2020 | NCT04616196 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | Nektar Therapeutics | Phase 1/2 | Completed | Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04616196) |
| June 16, 2020 | NCT04433585 | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) | Nektar Therapeutics | Phase 2 | Completed | Systemic Lupus Erythematosus | 291 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04433585) |
| June 1, 2020 | NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma... | Nektar Therapeutics | Phase 3 | Terminated | Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin) | 765 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04410445) |
| May 8, 2020 | NCT04380324 | A Study of NKTR-358 (LY3471851) in Healthy Participants | Nektar Therapeutics | Phase 1 | Completed | Healthy | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04380324) |
| October 23, 2019 | NCT04136756 | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | Nektar Therapeutics | Phase 1 | Completed | Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04136756) |
| October 21, 2019 | NCT04133116 | A Study of LY3471851 in Healthy Participants | Nektar Therapeutics | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04133116) |
| October 8, 2019 | NCT04119557 | A Study of LY3471851 in Participants With Psoriasis | Nektar Therapeutics | Phase 1 | Completed | Psoriasis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04119557) |
| September 9, 2019 | NCT04081350 | A Study of LY3471851 in Participants With Eczema | Nektar Therapeutics | Phase 1 | Completed | Dermatitis, Atopic | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04081350) |
| January 14, 2019 | NCT03802227 | A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid... | Nektar Therapeutics | Phase 1 | Terminated | Moderate to Severe Chronic Pain | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03802227) |
| December 24, 2018 | NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic... | Nektar Therapeutics | Phase 2 | Completed | Urinary Bladder Neoplasm, Neoplasm Metastasis | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03785925) |
| November 2, 2018 | NCT03729245 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase... | Nektar Therapeutics | Phase 3 | Terminated | Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | 623 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03729245) |
| June 14, 2018 | NCT03556007 | A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) | Nektar Therapeutics | Phase 1 | Completed | Systemic Lupus Erythematosus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03556007) |
| February 19, 2018 | NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | Nektar Therapeutics | Phase 1/2 | Terminated | Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell... | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03435640) |
| May 3, 2017 | NCT03138889 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | Nektar Therapeutics | Phase 1/2 | Terminated | Non-Small Cell Lung Cancer | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03138889) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 1/2 | 5 |
| Phase 2 | 11 |
| Phase 2/3 | 2 |
| Phase 3 | 8 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 27 |
| Terminated | 8 |
| Recruiting | 2 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Colorectal Neoplasms | 5 |
| Melanoma | 4 |
| Neoplasm Metastasis | 4 |
| Carcinoma, Renal Cell | 3 |
| Breast Neoplasms | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Neoplasms | 3 |
| Low Back Pain | 2 |
| Chronic Pain | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Carcinoma, Transitional Cell | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Recurrence | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Stomach Neoplasms | 1 |
| Alopecia Areata | 1 |
| Head and Neck Neoplasms | 1 |
| Ovarian Neoplasms | 1 |
| Carcinoma, Merkel Cell | 1 |
| Sarcoma | 1 |
| Osteoarthritis, Knee | 1 |
| Colitis, Ulcerative | 1 |
| Multiple Myeloma | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Lodges in the United States](https://specstream.ai/data/businesses/lodges/united-states)
- [Infectious disease clinics in the United States](https://specstream.ai/data/businesses/infectious-disease-clinics/united-states)
- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [Farm equipment repair companies in the United States](https://specstream.ai/data/businesses/farm-equipment-repair-companies/united-states)
- [Door suppliers in the United States](https://specstream.ai/data/businesses/door-suppliers/united-states)
- [Colleges and universities in the United States](https://specstream.ai/data/businesses/colleges-and-universities/united-states)
